Sezary Syndrome clinical trials

The registry lists 367 studies for Sezary Syndrome across more than 10 countries. 24 are recruiting or about to start. 9 of them are mainly about Sezary Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Sezary Syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 231
Terminated: 67
Withdrawn: 19
Recruiting: 17
Status unknown: 15
Active, not recruiting: 10

Phase

Phase 1: 151
Phase 2: 128
Phase 3: 27
Early Phase 1: 3
Phase 4: 3

Where

United States: 308
Italy: 25
Germany: 21
France: 17
Switzerland: 16
United Kingdom: 15

Who runs them

National Cancer Institute (NCI) (48) · Fred Hutchinson Cancer Center (32) · City of Hope Medical Center (17) · Northwestern University (17) · Mayo Clinic (13) · Memorial Sloan Kettering Cancer Center (12) · Case Comprehensive Cancer Center (12) · European Organisation for Research and Treatment of Cancer - EORTC (11)

What is being tested here

Drugs under test in Sezary Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Mogamulizumab	2	1	5
Cyclophosphamide	1	1	16
Lenalidomide	1	1	9
Cosibelimab	1	0	1
Golidocitinib	1	0	1
Aclarubicin	1	0	1
Vincristine	1	0	1
Prednisone	1	0	1
DT-7012	1	0	1
Fenretinide	1	0	1

Drug classes tested here Immune checkpoint inhibitors 2 open · Alkylating agents 1 open · Corticosteroids 1 open · Tyrosine kinase inhibitors (TKIs) 1 open · Antimitotic agents 1 open

Coming up

0phase 3 studies under way

10studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 10

Dec 2026Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome · Stanford University
Dec 2026A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma · Peking University First Hospital
Jan 2027A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab · City of Hope Medical Center
Feb 2027Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome · Washington University School of Medicine
Apr 2027Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. · Lund University Hospital
Jul 2027Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients · Memorial Sloan Kettering Cancer Center
Jul 2027Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome · Memorial Sloan Kettering Cancer Center
Sep 2027Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers · National Cancer Institute (NCI)
Oct 2027Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD) · Assistance Publique - Hôpitaux de Paris
Nov 2027Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study · Assistance Publique - Hôpitaux de Paris

Who these studies take

Of the 17 Sezary Syndrome studies recruiting now, 13 (76%) set no upper age limit and 1 (6%) stop at 75 or younger. 1 (6%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (6%) take healthy volunteers.

Recruiting studies that take each age, of 17
Age	Women	Men
10	1 (6%)	1 (6%)
18	15 (88%)	15 (88%)
30	16 (94%)	16 (94%)
40	16 (94%)	16 (94%)
50	16 (94%)	16 (94%)
65	17 (100%)	17 (100%)
75	17 (100%)	17 (100%)
85	16 (94%)	16 (94%)

Across all 367 studies, recruiting or not: 18% stop at 75 or younger and 10% at 65; 25% take children; 0% are for women only and 1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Sezary Syndrome studies take

Of 31 phase 2 interventional studies under Sezary Syndrome, half reached primary completion within 64 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	55 mo28–80 · 18 studies	—	—
Phase 2	64 mo39–110 · 31 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Newly registered2

Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary SyndromeNov 9, 2026NCT07926893
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid TumorsOct 27, 2026NCT07899632

Studies

Recruiting first, then most recently updated. Showing 50 of 367. Browse all 367 → or search them.